Actively Recruiting
Efficacy of the NXSignal Device for the Treatment of Anterior Cruciate Ligament Injuries
Led by University of Las Palmas de Gran Canaria · Updated on 2025-08-28
40
Participants Needed
1
Research Sites
239 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Injury to the anterior cruciate ligament (ACL) is very common among sports professionals and the general population \[. Unlike other joint injuries, it is reversible, but it can damage adjacent tissues, particularly the meniscus, and catalyze knee osteoarthritis. ACL injury produces instability, joint mechanical alteration, which can lead to degenerative joint diseases. The goal of treating the injury will be to prevent symptomatic instability, restore normal knee kinematics, and prevent degenerative joint disease . Its usual treatment is surgical and therefore contributes to a significant cost for the health system, both for the surgeries themselves, and for the rehabilitation and subsequent recovery processes. Within recovery therapies, in some cases, and given their popularity within the world of physiotherapy, electrotherapy techniques are proposed, primarily transcutaneous electrical nerve stimulation-type techniques with action on the muscular system and analgesia. An early intervention with neuromuscular electrostimulation electrotherapy (NMES) combined with repeated exercises is effective for the recovery of strength and restoration of the biomechanical symmetry of the limb. There is a diversity of opinions and disparate results regarding the use of this type of technique , in any case, it has been shown that electrical stimulation favors cell migration and joint tissue regeneration.
CONDITIONS
Official Title
Efficacy of the NXSignal Device for the Treatment of Anterior Cruciate Ligament Injuries
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Over 16 years old
- Mentally competent and in normal condition to participate
- No previous knee surgeries
- Able to complete study questionnaires
You will not qualify if you...
- Presence of contraindications for treatment with NESA XSIGNAL4, including pacemakers, internal bleeding, poor skin condition, ulcerations or wounds, acute fever, thrombophlebitis, or electricity phobia
- Not having signed informed consent
- Urgent surgical interventions
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Las Palmas de Gran Canaria
Las Palmas de Gran Canaria, Las Palmas, Spain, 35016
Actively Recruiting
Research Team
A
Aníbal Báez Suárez, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here